TIDMAKT
RNS Number : 3989R
Ark Therapeutics Group PLC
03 November 2011
ARK THERAPEUTICS GROUP PLC
Ark Therapeutics signs manufacturing agreement with University
of Glasgow
London, UK - 3 November 2011, Ark Therapeutics Group plc ("Ark")
is pleased to announce that it has signed a manufacturing agreement
with University of Glasgow's Institute of Cardiovascular and
Medical Sciences under which Ark will provide full manufacturing
and related services to support the development of the Institute's
gene-therapy programme for the treatment of vein graft failure
associated with coronary artery bypass surgery. The contract was
awarded following Ark's success in an open competitive tender
process under public body procurement rules.
Ark will manufacture for University of Glasgow cGMP grade
adenoviral vector expressing TIMP3 gene to be administered ex vivo
to vein grafts at the time of coronary artery bypass surgery in the
University's first-in-man Phase I/II trial to reduce vein graft
failure. Financial details of the agreement were not disclosed.
Martyn Williams, CEO of Ark commented: "We are delighted to
announce this agreement with the University of Glasgow for their
highly innovative gene-therapy programme in heart bypass surgery.
Our success in this competitive tender exercise further
demonstrates that Ark is establishing itself as a leading provider
of viral manufacturing services utilising our world leading
expertise in this arena."
Professor Anna Dominiczak, Head of the College of Medical,
Veterinary and Life Sciences at the University of Glasgow, said:
"This research, to prevent vein graft failure, is a very important
development. It is crucial that we work with an experienced company
for provision of clinical grade reagents for our clinical trial,
which if successful will make a substantial difference to the
long-term success of heart bypass procedures."
Andrew Baker, British Heart Foundation Professor of
Translational Cardiovascular Sciences and Principal Investigator on
the trial at the University of Glasgow, said: "The adenoviral
vector forms the centre piece of this clinical trial which has been
co-funded by the UK's Medical Research Council and the British
Heart Foundation. The trial will take place at the Golden Jubilee
National Hospital, Glasgow. We are delighted to partner with Ark in
this venture which has the potential to transform heart bypass
treatment."
For further information please contact:
Ark Therapeutics Group plc Tel: + 44 (0)20 7388 7722
Martyn Williams, CEO
Iain Ross, Chairman
FTI Consulting Tel: +44 (0)20 7831 3113
Ben Atwell
Susan Quigley
Ark Therapeutics Group plc
Ark Therapeutics Group plc is a specialist healthcare group (the
"Group") addressing high value areas of unmet medical need within
vascular disease and cancer. These are large and growing markets,
where opportunities exist for effective new products to generate
significant revenues.
Ark has an early stage pipeline emanating from collaborations
with University College, London and the AI Virtanen Institute in
Kuopio, Finland, the development of which it intends to progress in
collaboration with pharmaceutical and biotech partners.
In addition Ark has the ability to off-set a proportion of its
R&D costs and to generate sustainable revenues through the
exploitation of its proprietary technology platform, process
development, scale-up and manufacturing capabilities on behalf of
third parties.
Ark has its origins in businesses established in the mid-1990s
by Professor John Martin of University College London and Professor
Seppo Yla-Herttuala of the AI Virtanen Institute at the University
of Kuopio, Finland, both of whom remain consultants on the
Company's research and development programmes.
Ark's shares were first listed on the London Stock Exchange in
March 2004 (AKT.L).
The Institute of Cardiovascular and Medical Sciences of the
University of Glasgow
The Institute includes both academic clinicians, scientists who
are responsible for research, teaching and the delivery of clinical
services within Glasgow.
The groups are based across Glasgow and the largest are sited
within the Gilmorehill Campus in the purpose-built British Heart
Foundation Cardiovascular Research Centre, which houses
state-of-the-art laboratories, 3 T MRI Imaging, Confocal
Microscopy, high throughput genotyping facilities.
There is also a fully staffed Clinical Research Facility within
the Centre, jointly run with NHS Greater Glasgow & Clyde as
part of the network of CRFs in the City. This building was opened
in 2006, as a result of a generous donation by the British Heart
Foundation and a fund raising effort by the University of
Glasgow.
Facilities in the West Medical and Davidson Buildings, house
some ground breaking researchers and laboratories the area of
electrophysiology. In addition there are other groups looking at
sports and exercise science. This includes interests in performance
athletes and the use of exercise in assessment and management of
common medical conditions.
Other current research includes the development of novel
biological markers (haematological, biochemical and
electrophysiological) in cardiovascular disease and ageing. There
is also an extensive programme of research in stroke and
cerebrovascular disease extending from acute stroke imaging and
drug treatment (based in the Western Infirmary) to rehabilitation
and assessment of care pathways (in Glasgow Royal Infirmary).
This announcement includes "forward-looking statements" which
include all statements other than statements of historical facts,
including, without limitation, those regarding the Group's
financial position, business strategy, plans and objectives of
management for future operations (including development plans and
objectives relating to the Group's products and services), and any
statements preceded by, followed by or that include forward-looking
terminology such as the words "targets", "believes", "estimates",
"expects", "aims", "intends", "will", "can", "may", "anticipates",
"would", "should", "could" or similar expressions or the negative
thereof. Such forward-looking statements involve known and unknown
risks, uncertainties and other important factors beyond the Group's
control that could cause the actual results, performance or
achievements of the Group to be materially different from future
results, performance or achievements expressed or implied by such
forward-looking statements. Such forward-looking statements are
based on numerous assumptions regarding the Group's present and
future business strategies and the environment in which the Group
will operate in the future. Among the important factors that could
cause the Group's actual results, performance or achievements to
differ materially from those in forward-looking statements include
those relating to Ark's funding requirements, regulatory approvals,
clinical trials, reliance on third parties, intellectual property,
key personnel and other factors. These forward-looking statements
speak only as at the date of this announcement. The Group expressly
disclaims any obligation or undertaking to disseminate any updates
or revisions to any forward-looking statements contained in this
announcement to reflect any change in the Group's expectations with
regard thereto or any change in events, conditions or circumstances
on which any such statements are based. As a result of these
factors, readers are cautioned not to rely on any forward-looking
statement.
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGRFSSFAEFFSEFF
Premier Veterinary (LSE:PVG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Premier Veterinary (LSE:PVG)
Historical Stock Chart
From Jul 2023 to Jul 2024